Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Stephanie Kenney currently holds 33,085 shares of Atrium Therapeutics, Inc. (RNA), valued at approximately $0. This represents their equity stake as See Remarks.
Based on SEC Form 4 filings, Stephanie Kenney has been a net neutral trader of RNA stock. They have purchased $0 and sold $0 worth of shares.
Stephanie Kenney's most recent insider trade was on Sep 18, 2026, when they sold 2,375 shares at $8.95 per share.
Stephanie Kenney serves as See Remarks at Atrium Therapeutics, Inc. (RNA). They have executed 3 insider transactions totaling $0 over their tenure at the company.
Stephanie Kenney holds the position of See Remarks at Atrium Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 1 years and currently hold a stake valued at $0.
Stephanie Kenney has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Stephanie Kenney was on Sep 18, 2026, when they sold $21.3K worth of RNA shares. This transaction involved 2,375 shares at $8.95 per share.
Stephanie Kenney currently owns 33,085 shares of Atrium Therapeutics, Inc. (RNA), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Stephanie Kenney's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Stephanie Kenney has 3 Form 4 filings on record as an insider at Atrium Therapeutics, Inc..
Set alerts for Stephanie Kenney and 40,000+ other insiders.